LANDSCAPE OF KRAS G12C MUTATIONS IN GENITOURINARY MALIGNANCIES

被引：0
|
作者：
Rebecca, Sager A.
Michael, Basin F.
Hanan, Goldberg
Jeffrey, Ross S.
Gennady, Bratslavsky
Joseph, Jacob M.
Petros, Grivas
Andrea, Necchi
机构：
[1] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[3] Univ Vita Salute San Raffaele, Milan, Italy
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2024年 / 42卷
关键词：
D O I：
10.1016/j.urolonc.2024.01.198
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
161
引用
收藏
页码：S69 / S69
页数：1
相关论文
共 50 条
  • [1] The emerging target KRAS G12C in genitourinary malignancies
    Grivas, Petros
    Necchi, Andrea
    Bratslavsky, Gennady
    Shapiro, Oleg
    Jacob, Joseph
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Keith
    Williams, Erik
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Hemmerich, Amanda
    Schrock, Alexa Betzig
    Chung, Jon
    McGregor, Kimberly
    Reddy, Prasanth
    Alexander, Brian Michael
    Sokol, Ethan
    Danziger, Natalie
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Targeting KRAS G12C mutations in colorectal cancer
    Zhao, Ming-He
    Wu, Ai-Wen
    GASTROENTEROLOGY REPORT, 2023, 11
  • [3] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [4] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [5] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [6] KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
    Loong, Herbert Ho-Fung
    Du, Nan
    Cheng, Chunyan
    Lin, Hanqing
    Guo, Jian
    Lin, Gen
    Li, Mingjiang
    Jiang, Tao
    Shi, Zhihua
    Cui, Yanzhi
    Jin, Xianfeng
    Yao, Jicheng
    Xing, Yutong
    Yao, Ming
    Wang, Kai
    Mok, Tony S. K.
    Liu, Lunxu
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 1759 - +
  • [7] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [8] Molecular Epidemiology of KRAS G12C Mutations in Chinese Lung Cancer Patients
    Loong, H.
    Du, N.
    Cheng, C.
    Lin, H.
    Guo, J.
    Lin, G.
    Li, M.
    Jiang, T.
    Shi, Z.
    Cui, Y.
    Jin, X.
    Yao, J.
    Xing, Y.
    Yao, M.
    Wang, K.
    Mok, T.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S426 - S426
  • [9] KRAS G12C mutations in non-small cell lung cancer
    Li, J. J.
    Wu, X. J.
    Farzin, M.
    Bray, V.
    Williamson, J.
    Pal, A.
    Yip, P. Y.
    Hagelamin, A.
    Ding, P.
    Nindra, U.
    Vinod, S.
    French, B.
    Chua, W.
    Gupta, R.
    Cooper, W. A.
    Wang, B.
    Lee, C. S.
    HISTOPATHOLOGY, 2024, 85 : 25 - 25
  • [10] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
    Lim, Tony Kiat Hon
    Skoulidis, Ferdinandos
    Kerr, Keith M.
    Ahn, Myung-Ju
    Kapp, Joshua R.
    Soares, Fernando A.
    Yatabe, Yasushi
    LUNG CANCER, 2023, 184
12345